Descrição
The interleukin (IL)-1 cytokine family currently consists of 11 members with pleiotropic functions in inflammation and cancer.IL-1α and IL-1β were the first members of the IL-1 family to be described, and they both signal through the same receptor, IL-1R.
Product Properties
Synonyms |
Interleukin-1 alpha; IL-1 alpha; Hematopoietin-1; IL1A; IL1F1; IL-1 ALPHA; IL1; IL-1A; IL1 |
Species |
Cynomolgus |
Source |
HEK293 |
Sequence |
Ser113-Ala271 |
Accession |
P79340 |
Tag |
No Tag |
Molecular Weight |
The protein has a predicted MW of 18.13 kDa. Due to glycosylation, the protein migrates to 26-33 kDa based on Bis-Tris PAGE result. |
Endotoxin |
< 1 EU/μg by the LAL method. |
Purity |
> 95% as determined by Bis-Tris PAGE; |
Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Appearance |
Lyophilized powder |
Shipping and Storage
-25 ~ -15 ° C storage, 1 year expiration date after receipt. After re-solution, store at 2 ~8 °C, 7 days expiration date. After re-dissolution, store at -85~-65°C, 3 months expiration date.
Compounding method
Centrifuge before opening the lid. Use distilled water to reconstitute lyophilized proteins at reconstitution concentrations greater than 100 μg/mL. it is recommended that proteins be portioned out for each experimental dosage upon first use to avoid repeated freeze-thawing.
Cautions
1. For your safety and health, please wear lab coat and disposable gloves.
2. This product is for scientific research purposes only.
Pagamento e segurança
Suas informações de pagamento são processadas com segurança. Não armazenamos detalhes do cartão de crédito nem temos acesso às informações do seu cartão de crédito.
Investigação
Você também pode gostar
Perguntas frequentes
O produto é apenas para fins de pesquisa e não se destina ao uso terapêutico ou diagnóstico em humanos ou animais. Os produtos e o conteúdo são protegidos por patentes, marcas registradas e direitos autorais de propriedade da
Certos aplicativos podem exigir direitos adicionais de propriedade intelectual de terceiros.